<DOC>
	<DOCNO>NCT00563576</DOCNO>
	<brief_summary>Many woman choose Depo-Provera birth control easy use effective . However , significant number Depo-Provera user experience irregular bleeding first 90 day . Many user discontinue first injection due irregular bleeding . This study evaluate effect use estrogen vaginal ring first 90 day Depo-Provera use see acceptable woman whether decrease irregular bleed first 90 day use increases continuation second injection .</brief_summary>
	<brief_title>Pilot Study Femring Estrogen Supplementation During Depo-Provera Initiation</brief_title>
	<detailed_description>Many woman choose depot medroxyprogesterone acetate ( DMPA ) contraception long-acting , highly effective , require minimal user involvement . One common side effect DMPA use first 90 day cycle irregular bleeding . There study report mean number bleeding day among DMPA user . A large World Health Organization ( WHO ) trial include ten international center menstrual data 748 woman use DMPA include 372 woman-years follow-up report 23.6 mean day spot bleed first cycle standard deviation 18.9 day ( WHO ) . Another study sponsor WHO ( n=575 ) report 25 % subject bleeding/spotting episode first cycle DMPA exceed 13 day . The number bleeding/spotting day number bleeding/spotting episode decrease successive reference period ( Said 1987 ) . Discontinuation rate high first injection relate irregular bleeding . Rates discontinuation first injection range 15-60 % around 30 % study ( Harel , Paul , Polaneczy , Lim , Hubacher , Sangi , Rickert ) . Several study note large percentage discontinuation first year DMPA use occur first injection ( Rickert , Hubacher , Lim ) . Irregular bleed uniformly cite one common reason discontinuation , account 17-60 % reason give ( Harel , Paul , Polaneczy , Lim , Sangi ) . An intervention prevent minimize irregular bleed first 90 day DMPA use could potentially minimize prevent bothersome side effect thus improve continuation . Few study examine effect prophylactic therapeutic estrogen supplementation irregular bleeding DMPA user . A randomized trial ( n=132 ) cyclic transdermal estradiol 0.1 mg/day ( Climara ) 3 month versus placebo woman initiate DMPA immediately post-abortion show difference continuation rate 12 month ; however , author study report high rate non-compliance study protocol lack adequate sample size detect difference ( Goldberg ) . This study report prophylactic estrogen supplementation DMPA user . Two study evaluate therapeutic estrogen supplementation DMPA user . In 1996 , WHO publish result trial woman use DMPA experience bleed episode great 7 day first second injection interval offer treatment . Subjects ( n=278 ) randomize 14 day course 50 mcg ethinyl estradiol , 2.5 mg oestrone sulphate , placebo . The author find subject treat ethinyl estradiol shorter median time cessation bleed few bleeding/spotting day ( Said 1996 ) . An observational study ( n=131 ) adolescent report vaginal bleeding DMPA treat monophasic oral contraceptive pill identify improvement bleed pattern high rate continuation receive treatment ( Rager ) . Estrogen supplementation appear effective placebo stop decrease bleed Norplant user . Women present spontaneous complaint prolong irregular bleeding randomly assign receive 20 day treatment combined oral contraceptive , 50 mcg ethinyl estradiol , placebo . Both combined oral contraceptive pill estradiol significantly effective placebo stop bleed decrease mean number bleed day treatment ( Alvarez ) . To summarize , prior study identify acceptable effective prophylactic intervention prevent minimize irregular bleed improve continuation rate DMPA user . The first cycle DMPA critical time intervention . Our study evaluate estrogen supplementation estrogen vaginal ring first 90 day DMPA use versus estrogen supplementation report acceptability , bleed pattern , continuation rate . FemringÂ® , estradiol vaginal ring currently use treatment postmenopausal symptom , provide 100 mcg estradiol per day one ring design 90 day consecutive use . This dose provide systemic level sufficient suppress vasomotor symptom postmenopausal woman ( Speroff ) . The vaginal ring would require minimal user involvement place time DMPA initiation . If acceptable effective , intervention could prevent minimize irregular bleed improve continuation rate highly effective contraceptive method .</detailed_description>
	<mesh_term>Metrorrhagia</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Women age 18 old initiating DepoProvera contraception English Spanishspeaking Have negative urine pregnancy test Contraindications either DepoProvera Femring ( estrogen vaginal ring ) Have use DepoProvera Mirena prior 6 month Have induce abortion , spontaneous abortion , birth prior 8 week</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Depo-Provera</keyword>
	<keyword>Medroxyprogesterone Acetate</keyword>
	<keyword>Metrorrhagia</keyword>
	<keyword>Irregular Bleeding</keyword>
</DOC>